Have a personal or library account? Click to login
Ketamine used in the therapy of depressive disorders impacts protein profile, proliferation rate, and phagocytosis resistance of enterococci Cover

Ketamine used in the therapy of depressive disorders impacts protein profile, proliferation rate, and phagocytosis resistance of enterococci

Open Access
|Aug 2022

Figures & Tables

Fig. 1

Characteristics of two types of strains identified by response to ketamine
Characteristics of two types of strains identified by response to ketamine

Fig. 2

Changes in cytotoxicity and phagocytosis in two groups of Enterococcus faecalis strains. The value 1.00 means no changes when compared with bacteria not treated with ketamine
Changes in cytotoxicity and phagocytosis in two groups of Enterococcus faecalis strains. The value 1.00 means no changes when compared with bacteria not treated with ketamine

Source of strains

SourceNumber of strains
Upper respiratory tract6
Cervical canal4
Vagina4
Wound5
Urine (> 106 cfu/mL)4
Bedsore3
Sperm1

Changes of relative values of protein peak after incubation of the enterococcal strains with ketamine_ Group A+: strains increasing proliferation when cultured with ketamine; group B+ strains inhibited by ketamine; group A and B – strains cultured without ketamine_ Grey bars: peaks typical for Enterococcus faecalis according to Stępień-Pyśniak D et al_ [24]_ Dark grey bars: the highest protein peak for all the measurements, considered as baseline for observed levels in other protein peaks (group A and B) and after the exposure to ketamine (group A+ and B+)_ Green color underlines the increase of peak value; the red color indicates decreased or missing peak when compared to strains not exposed to ketamine

Referencem/zGroup AGroup A +Group BGroup B +
Stępień-Pyśniak D22116788025
2663290017
342129293320
36692635240
4439100100100100
477828372217
536153403862
608414161510
62311415180
640325243126
683931324038
732642594213
75722302319
891112152112
954427352326
Language: English
Page range: 333 - 338
Submitted on: Jan 3, 2022
Accepted on: May 11, 2022
Published on: Aug 9, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2022 Tomasz Jarzembowski, Agnieszka Daca, Wiesław J. Cubała, Marek Bronk, Łukasz Naumiuk, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.